Introduction to AP2B1 (G163)

Target Name: AP2B1

NCBI ID: G163

AP2B1

Introduction to AP2B1

AP2B1, also known as Adaptor protein complex 2 subunit beta-1, plays a crucial role in various cellular processes, making it a promising drug target and biomarker. This article aims to explore the significance of AP2B1 in human health and disease and shed light on its potential as a therapeutic target.

The Function and Importance of AP2B1:

AP2B1 is a subunit of the adaptor protein complex 2 (AP-2) which is responsible for clathrin-mediated endocytosis. Endocytosis is a vital process in which cells internalize extracellular material and membrane components, allowing them to regulate various cellular functions. AP-2 is involved in the formation of clathrin-coated vesicles, which mediate the internalization of cargo molecules, including receptors and signaling proteins.

One of the key functions of AP2B1 is to interact with the plasma membrane and bind to cargo proteins. This interaction facilitates the recruitment of clathrin and other accessory proteins necessary for the formation of clathrin-coated vesicles. By regulating endocytosis, AP2B1 plays a pivotal role in multiple physiological processes, including signal transduction, nutrient uptake, and cell membrane homeostasis.

AP2B1 as a Drug Target:

Given its essential role in endocytosis, AP2B1 presents an attractive target for therapeutic intervention. Disrupting the function of AP2B1 can potentially block the internalization of specific receptors or interfere with the uptake of essential nutrients by cancer cells, thus inhibiting their proliferation and survival.

A recent study highlighted the potential of AP2B1 as a drug target for cancer therapy. By selectively suppressing AP2B1 expression in lung cancer cells, researchers observed a significant reduction in tumor growth and metastasis. This demonstrates the critical role of AP2B1 in tumor progression and its potential as a therapeutic target for various cancers.

Furthermore, AP2B1 has been implicated in viral infections. Several viruses, including herpes simplex virus, human immunodeficiency virus (HIV), and respiratory syncytial virus, exploit AP-2 mediated endocytosis for viral entry into host cells. By targeting AP2B1, researchers might be able to develop novel antiviral therapies to prevent viral entry and subsequent infections.

AP2B1 as a Biomarker:

Apart from its potential as a drug target, AP2B1 also shows promise as a biomarker for various diseases. Biomarkers are measurable indicators that can be used to diagnose diseases, monitor their progression, and evaluate treatment response.

In the field of cancer research, AP2B1 expression has been correlated with tumor stage and patient prognosis. High levels of AP2B1 have been associated with aggressive tumor behavior and poor survival rates in patients with breast, lung, and colorectal cancers. By detecting AP2B1 expression through immunohistochemistry or other molecular techniques, clinicians can potentially identify patients with a higher risk for disease progression and personalize treatment strategies accordingly.

Moreover, AP2B1 has been implicated in neurodegenerative disorders such as Alzheimer's disease. Studies have shown altered expression and localization of AP2B1 in affected brain regions of Alzheimer's patients. This suggests that AP2B1 may play a role in the pathogenesis of the disease and could be used as a biomarker for early diagnosis or monitoring disease progression.

Conclusion:

AP2B1, as a critical component of the AP-2 complex, plays a pivotal role in cellular processes like endocytosis. Its function as a drug target and biomarker holds significant promise for therapeutic development and disease management. By targeting AP2B1, scientists can potentially develop novel therapies for cancer and viral infections. Additionally, AP2B1 may serve as a valuable biomarker for diagnosing and monitoring the progression of various diseases, aiding in personalized treatment strategies. Further research and clinical studies are necessary to fully explore the potential of AP2B1 as a drug target and biomarker and translate it into clinical applications that improve patient outcomes.

Protein Name: Adaptor Related Protein Complex 2 Subunit Beta 1

Functions: Component of the adaptor protein complex 2 (AP-2). Adaptor protein complexes function in protein transport via transport vesicles in different membrane traffic pathways. Adaptor protein complexes are vesicle coat components and appear to be involved in cargo selection and vesicle formation. AP-2 is involved in clathrin-dependent endocytosis in which cargo proteins are incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) which are destined for fusion with the early endosome. The clathrin lattice serves as a mechanical scaffold but is itself unable to bind directly to membrane components. Clathrin-associated adaptor protein (AP) complexes which can bind directly to both the clathrin lattice and to the lipid and protein components of membranes are considered to be the major clathrin adaptors contributing the CCV formation. AP-2 also serves as a cargo receptor to selectively sort the membrane proteins involved in receptor-mediated endocytosis. AP-2 seems to play a role in the recycling of synaptic vesicle membranes from the presynaptic surface. AP-2 recognizes Y-X-X-[FILMV] (Y-X-X-Phi) and [ED]-X-X-X-L-[LI] endocytosis signal motifs within the cytosolic tails of transmembrane cargo molecules. AP-2 may also play a role in maintaining normal post-endocytic trafficking through the ARF6-regulated, non-clathrin pathway. During long-term potentiation in hippocampal neurons, AP-2 is responsible for the endocytosis of ADAM10 (PubMed:23676497). The AP-2 beta subunit acts via its C-terminal appendage domain as a scaffolding platform for endocytic accessory proteins; at least some clathrin-associated sorting proteins (CLASPs) are recognized by their [DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif. The AP-2 beta subunit binds to clathrin heavy chain, promoting clathrin lattice assembly; clathrin displaces at least some CLASPs from AP2B1 which probably then can be positioned for further coat assembly

The "AP2B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AP2B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets